Mr. Gavin Bogle reports

BLUEOCEAN NUTRASCIENCES INC. ANNOUNCES APPOINTMENT OF MARVIN HEUER TO THE BOARD OF DIRECTORS AND THE ISSUANCE OF OPTIONS

Blueocean Nutrasciences Inc. has appointed Dr. Marvin Heuer to Blueocean's board of directors effective Jan. 18, 2017.

Dr. Marvin Heuer, MD, is the founder and chief executive of Heuer M.D. Research Inc., a private SMO clinical research organization. Dr. Heuer is an internationally accomplished medical research physician and executive with more than 30 years of experience in international and domestic clinical research, and pharmaceutical and nutraceutical development. Along with the practice of medicine for over 40 years, Dr. Heuer has served as chief science officer for Iovate Health Sciences International, vice-president of clinical research, IntegraMed America, vice-president and director worldwide of research and development, SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline), vice-president of research and development, Wallace Laboratories (now Meda AB), and vice-president and medical director worldwide, Ayerst Laboratories (now Pfizer). Dr. Heuer's significant experience in R&D, regulatory and operations will provide invaluable insight for Blueocean's retail portfolio expansion.

"We are very pleased and fortunate to have Dr. Heuer join the board. As Blueocean's former partner in Pure Polar Labs Inc., Dr. Heuer has already provided invaluable assistance to Blueocean with its current product formulations and we look forward to working further with Dr. Heuer to develop new innovative health products," said Gavin Bogle, president and chief executive officer.

Dr. Heuer's appointment is subject to TSX Venture Exchange approval.

Blueocean also announces that the board has approved the issuance of 897,222 stock options to eligible participants of the company's stock option plan. The options vest over varying periods throughout 2017 and are exercisable into common shares of the company at an exercise price of 13.5 cents, over the next five years, all in accordance with the plan.

About Blueocean

Blueocean Nutrasciences is a Canadian-listed public company that is focused on developing sustainable, specialty nutraceutical products targeted at the rapidly growing natural health products markets, with a current focus on the $4-billion omega-3 heart health supplement market, the $9-billion joint health market and the $10-billion sports supplement market. Blueocean's proprietary shrimp oil ingredient contains high levels of naturally occurring astaxanthin, phospholipids, and omega-3 EPA and DHA, enabling the product to be targeted across all three markets described above.

Blueocean's consumer brand, Pure Polar omega-3 shrimp oil, contains over two times more omega-3 EPA and DHA, and 10 times more astaxanthin than typical retail krill oil brands, and contains phospholipids for better absorption of the essential nutrients.

We seek Safe Harbor.